Genentech agrees with US govt to lower costs for state Medicaid programs, encouraging global innovation, and increasing patient access.

In South San Francisco, California, Genentech, part of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has reached an agreement with the U.S. government to reduce costs for state Medicaid programs while also promoting innovation incentives in wealthy countries and enhancing patient access. The agreement aligns with the President's objectives outlined in a letter dated July 31st. Genentech has committed to fulfilling all four priorities specified in the letter. This commitment involves various measures to support these goals and improve patient accessibility.